Analytical decision tree model used in this economic evaluation. The decision tree model depicts the most important clinical and cost considerations in patients suspected of having HIT in whom heparins have been suspended. At the decision point, 3 nonheparin anticoagulants were considered: argatroban, fondaparinux, and rivaroxaban. Patients who received any of these medications underwent laboratory HIT diagnostics. Differences in the eventual costs and outcomes (ie, complications or no complications) per drug form the basis of this analysis. All model inputs and their references are explained in the Supplementary Table 1. p, standardized probability of event; r, incidence rate; VTE, venous thromboembolism.